

DAFTAR PUSTAKA

- Arifin, A. L. (2016). Panduan terapi diabetes mellitus tipe 2 terkini. *Repositori Unpad*, 13–25.
http://pustaka.unpad.ac.id/wpcontent/uploads/2011/03/panduan_terapi_diabetes_mellitus.pdf
- Berryman, L. Y. (2000). Pharmacotherapy Handbook. 2nd Edition. In *The Annals of Pharmacotherapy* (Vol. 34, Issue 12). <https://doi.org/10.1345/aph.10237>
- BPOM Badan Pengawasan Makanan dan Obat. 2014. Pusat informasi obat nasional BPOM. Jakarta: BPOM RI.
- Care, D., & Suppl, S. S. (2018). Classification and diagnosis of diabetes: Standards of medical care in Diabetesd2018. *Diabetes Care*, 41(January), S13–S27.
<https://doi.org/10.2337/dc18-S002>
- Care, D., & Suppl, S. S. (2019). 2. Classification and diagnosis of diabetes: Standards of medical care in diabetesd2019. *Diabetes Care*, 42(January), S13–S28.
<https://doi.org/10.2337/dc19-S002>
- Decroli Eva. 2019. Diabetes melitus tipe 2. Padang : Fakultas Kedokteran, Universitas Andalas.
- Depkes RI, 2005; Undang-Undang Republik Indonesia Nomor : 23 tahun 2005 Tentang Kesehatan; Jakarta; Hal 1. Fisioterapi Indonesia; Jakarta; Hal.5.
- Derosa, G., Carbone, A., Franzetti, I., Querci, F., Fogari, E., Bianchi, L., Bonaventura, A., Romano, D., Cicero, A. F. G., & Maffioli, P. (2012). Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β -cell function and insulin resistance in type 2 diabetic patients. *Diabetes Research and Clinical Practice*, 98(1), 51–60.
<https://doi.org/10.1016/j.diabres.2012.05.022>
- Ewadh, M. J. (2014). Evaluation of Amylase Activity in Patients with Type 2 Daibetes Mellitus. *American Journal of BioScience*, 2(5), 171.
<https://doi.org/10.11648/j.ajbio.20140205.11>
- Fatimah RN. 2015. Diabetes Melitus Tipe 2. *J Majority* 4 (5): 93-101
- Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J., & Broedl, U. C. (2013). Long-term safety and efficacy of empagliflozin, sitagliptin, and

- metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. *Diabetes Care*, 36(12), 4015–4021. <https://doi.org/10.2337/dc13-0663>
- Fitriyani. (2012). Universitas Indonesia Faktor Risiko Diabetes Melitus Tipe 2 Di Puskesmas Kecamatan Citangkil Dan Puskesmas Kecamatan Pulo Merak , Kota Cilegon Universitas Indonesia Faktor Risiko Diabetes Melitus Tipe 2 Di Puskesmas Kecamatan Pulo Merak ,. *Faktor Resiko Diabetes Melitus TIPE 2 DI Puskesmas*, 1–102
- Flory, J. H., Small, D. S., Cassano, P. A., Brillon, D. J., Mushlin, A. I., & Hennessy, S. (2014). Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin. *Journal of Comparative Effectiveness Research*, 3(1), 29–39. <https://doi.org/10.2217/cer.13.87>
- Fonseca, V., Staels, B., Morgan, J. D., Shentu, Y., Golm, G. T., Johnson-Levonas, A. O., Kaufman, K. D., Goldstein, B. J., & Steinberg, H. (2013). Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, 27(2), 177–183. <https://doi.org/10.1016/j.jdiacomp.2012.09.007>
- Green, J., Karen, K., & Cox, M. E. (2010). Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 363. <https://doi.org/10.2147/dmsott.s10195>
- Hanum, N. N. (2013). Hubungan Kadar Glukosa Darah Puasa dengan Profil Lipid pada Pasien Diabetes Melitus tipe 2 di Rumah Sakit Umum Daerah Cilegon periode Januari-April 2013. *Program Studi Pendidikan Dokter Fakultas Kedokteran Dan Ilmu Kesehatan Universitas Islam Negeri Syarif Hidaytullah, April*, 1–70.
- Ikatan Dokter Anak Indonesia. (2015). Konsensus Nasional Pengelolaan Pengelolaan Diabetes Melitus Tipe-2 pada Anak dan Remaja. *UKK Endokrinologi Anak Dan Remaja, IDAI*, 40.
- Kemenkes RI. (2014). Situasi dan Analisis Diabetes. *INFODATIN : Pusat Data Dan Informasi Kementerian Kesehatan Republik Indonesia*, 1(Waspada Diabetes), 8.
- Kikuchi, M., Kaku, K., Odawara, M., Momomura, S. I., & Ishii, R. (2012). Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: A double-blind, 28 weeks' treatment, comparative

- study. *Current Medical Research and Opinion*, 28(6), 1007–1016.
<https://doi.org/10.1185/03007995.2012.694361>
- Kim, H. soon, Kim, D. man, Cha, B. soo, Park, T. S., Kim, K. ah, Kim, D. lim, Chung, C. H., Park, J. hyun, Jang, H. C., & Choi, D. seop. (2014). Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. *Journal of Diabetes Investigation*, 5(6), 701–708. <https://doi.org/10.1111/jdi.12201>
- Ku, E. J., Lee, D. H., Jeon, H. J., & Oh, T. K. (2019). Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. *Diabetes Research and Clinical Practice*, 151, 65–73. <https://doi.org/10.1016/j.diabres.2019.04.008>
- Latarissa A. 2015. Buku pedoman rekam medik. Makassar: Health and medicine.
- Lathifah, N. L. (2017). Hubungan Durasi Penyakit dan Kadar Gula Darah Dengan Keluhan Subyektif Penderita Diabetes Melitus. *Jurnal Berkala Epidemiologi*, 5(2), 231–239. <https://doi.org/10.20473/jbe.v5i2.2017.231-239>
- Liu, S. C., Chien, K. L., Wang, C. H., Chen, W. C., & Leung, C. H. (2013). Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. *Endocrine Practice*, 19(6), 980–988. <https://doi.org/10.4158/EP13148.OR>
- Made, P., & Pathni, S. D. (2019). Terapi Diabetes dengan SGLT-2 Inhibitor. *Cdk-277*, 46(6), 452–456.
- NIIDK. (2014). Causes of diabetes. *National Institute of Diabetes and Digestive and Kidney Diseases*, 253(1718), 37. <https://doi.org/10.1049/et:20081020>
- Nurcahyadi, I. P. A. (2010). Pankreatitis Akut Dengan Serum Amilase 1071 . 90 U / L Dan Serum Lipase 1111 . 00 U / L : Sebuah Laporan Kasus Acute Pancreatitis With Amilase Serum of 1071 . 90 U / L and Lipase Serum of 1111 . 00 U / L : a Case Report. *Bagian/SMF Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Udayana/RSUP Sanglah Denpasar*, 1–7.
- Pareek, A., Chandurkar, N. B., Salkar, H. R., Borkar, M. S., & Tiwari, D. (2013). Evaluation of Efficacy and Tolerability of Glimepiride and Metformin

- Combination. *American Journal of Therapeutics*, 20(1), 41–47.
<https://doi.org/10.1097/mjt.0b013e3181ff7c63>
- Pareek, Anil, et al. "Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin." *American journal of therapeutics* 17.6 (2010): 559-565.
- PERKENI Perkumpulan Endokrinologi Indonesia. 2011. Konsensus pengendalian dan pencegahan Diabetes Mellitus tipe 2 di Indonesia 2011. Jakarta: PERKENI.
- PERKENI Perkumpulan Endokrinologi Indonesia. 2015. Konsensus pengendalian dan pencegahan Diabetes Mellitus tipe 2 di Indonesia 2011. Jakarta: PERKENI.
- PERKENI. (2011). Konsensus Diabetes Mellitus. *Perkeni*, 16(1994), 1–27.
[http://eprints.ums.ac.id/37501/6/BAB II.pdf](http://eprints.ums.ac.id/37501/6/BAB%20II.pdf)
- Prabawati, R. K. (2012). Mekanisme Seluler dan Molekular Resistensi Insulin. *Tugas Biokimia Program Pasca Sarjana Ilmu Biomedik Program Double Dolgree Neurologi Fakultas Kedokteran Universitas Brawijaya Malang*, 1, 1–15.
- Riset Kesehatan Dasar (Riskesdas) (2018). Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018.
http://www.depkes.go.id/resources/download/infoterkini/materi_rakorpop_2018/Hasil%20Riskesdas%202018.pdf
- Shubbrook, J., Butts, A., Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Skolnik, N., Bradley, S., Jaffa, F. M., Herman, W. H., Kalyani, R. R., Cherrington, A. L., Coustan, D. R., De Boer, I., James, R., Feldman, H., Florez, H. J., Koliwad, S., Maryniuk, M., ... Ratner, R. (2017). Standards of medical care in diabetes—2017 abridged for primary care providers. *Clinical Diabetes*, 35(1), 5–26.
<https://doi.org/10.2337/cd16-0067>
- Soegondo, S., 2011. Diagnosis dan Klasifikasi Diabetes Melitus Terkini dalam: Soegondo, S., Soewondo, P., Subekti, I., Editor. Penatalaksanaan Diabetes Melitus Terpadu bagi dokter maupun edukator diabetes. Jakarta: Fakultas Kedokteran Universitas Indonesia.
- Soelistijo, S. A., Lindarto, D., Decroli, E., Permana, H., Sucipto, K. W., Kusnadi, Y., Budiman, & Ikhsan, R. (2019). Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. *Perkumpulan Endokrinologi Indonesia*,

- 1–117. <https://pbperkeni.or.id/wp-content/uploads/2020/07/Pedoman-Pengelolaan-DM-Tipe-2-Dewasa-di-Indonesia-eBook-PDF-1.pdf>
- Statements, P. (2012). Standards of medical care in diabetes - 2012. *Diabetes Care*, 35(SUPPL. 1). <https://doi.org/10.2337/dc12-s011>
- Suryajaya, P. I. (2015). *CONTINUING CONTINUING DEVELOPMENT PROFESSIONAL MEDICAL DEVELOPMENT Dapaglifl ozin : Terapi Baru untuk Diabetes Melitus*. 42(11), 817–822.
- Taskinen, M., Rosenstock, J., Tamminen, I., Kubiak, R., Patel, S., Dugi, K. A., & Woerle, H. (2011). Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. *Diabetes, Obesity and Metabolism*, 13(1), 65–74. <https://doi.org/10.1111/j.1463-1326.2010.01326.x>
- Wang, W., Yang, J., Yang, G., Gong, Y., Patel, S., Zhang, C., Izumoto, T., & Ning, G. (2016). Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial. *Journal of Diabetes*, 8(2), 229–237. <https://doi.org/10.1111/1753-0407.12284>
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2015). Pharmacotherapy Handbook. In *AIAA Guidance, Navigation, and Control Conference*.
- WHO. 2006. Guidelines for the prevention, management and care of Diabetes Mellitus. Mediterania Timur: *World Health Organization (WHO)*.
- World Health Organization. (2016a). Diabetes facts, 1–2. <https://doi.org/10.1097/00152193-198704000-00001>
- World Health Organization. (2016b). Global Report on Diabetes. Isbn, 978, 88. <https://doi.org/ISBN 978 92 4 156525 7>
- Yu, H. M., Kim, S. J., Chun, S. W., Park, K. Y., Lim, D. M., Lee, J. M., Hong, J. H., & Park, K. S. (2019). A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. *Diabetes Research and Clinical Practice*, 155, 107796. <https://doi.org/10.1016/j.diabres.2019.107796>

Zhang, Mei, et al. "*Dapagliflozin treatment for type 2 diabetes: a systematic review and meta- analysis of randomized controlled trials.*" *Diabetes/metabolism research and reviews* 30.3 (2014): 204-221.